Bone Therapeutics closes Series D funding round

Bone Therapeutics, a biopharmaceutical company focused on cell therapy products for the treatment of bone diseases, has successfully closed a Series D funding round, raising €7.7m (£6.6m) from current investors and the Walloon Region.

The funds raised will be used to accelerate the development of the company’s bone cell therapy pipeline, as well as to sustain the Phase III clinical trials for the PREOB product.

PREOB is an autologous bone cell therapy product that is currently in Phase III clinical trials for the treatment of osteonecrosis and non-union fractures.